


1. Un compuesto representado por la Fórmula (VIId-2), o una sal farmacéuticamente aceptable del mismo:



en donde

m_3 es 0, 1 o 2;

R_{21} en cada aparición es un halógeno;

R_{22} es halógeno;

R_{23} es hidrogeno o halógeno;

n en cada aparición se selecciona independientemente de 0, 1 o 2;

E es $-C(R_{10})_2$;

R_{10} en cada aparición se selecciona independientemente del grupo que consiste en hidrógeno, halógeno, $-CN$, $-NO_2$, $-C_1-C_6$ alquilo sustituido o no sustituido, $-C_2-C_8$ alqueno sustituido o no sustituido, $-C_2-C_8$ alquino opcionalmente sustituido, $-C_3-C_8$ cicloalquilo sustituido o no sustituido, heterociclos de 3- a 8-miembros sustituidos o no sustituido, arilo sustituido o no sustituido, heteroarilo opcionalmente sustituido o no sustituido, y $-L_1-R_1$; en donde L_1 es $-O-$, $-S-$, $-NR_1-$, $-C(O)-$, $-C(O)O-$, $-OC(O)-$, $-C(O)N(R_1)-$, $-N(R_1)C(O)-$, $-OC(O)N(R_1)-$, $-N(R_1)C(O)O-$, $-N(R_1)C(O)N(R_1)-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R_1)-$, $-N(R_1)S(O)_2-$; R_1 en cada aparición se selecciona independientemente del grupo que consiste en hidrógeno y $-C_1-C_6$ alquilo sustituido o no sustituido; alternatively, dos grupos R_{10} adyacentes se toman junto con los átomos de carbono o nitrógeno al cual están unidos para formar un enlace doble olefínico o imínico o un anillo fusionado; o dos grupos R_{10} geminales juntos forman un oxo, una olefina opcionalmente sustituida, una oxima opcionalmente sustituida, o un anillo espiro adicional; y

R_{30} es hidrogeno o un $-C_1-C_6$ alquilo sustituido o no sustituido.

2. El compuesto de la reivindicación 1 donde

Cada R_{10} es independientemente hidrogeno, un halógeno, hidroxilo o C_1-C_3 alquilo opcionalmente sustituido; y

R_{30} es hidrogeno.

3. El compuesto de cualquiera de las reivindicaciones 1 o 2 donde








R_{21} en cada aparición es flúor;

R_{22} es flúor o cloro; y










R_{23} es hidrogeno o flúor.









4. El compuesto de la reivindicación 3 donde R_{23} es flúor.

5. El compuesto de la reivindicación 1, seleccionado de los compuestos expuestos más abajo o una sal farmacéuticamente aceptable de éste:

Compuesto	Estructura
44	
60	
120	
127	
129	
131	
132	









133	
134	
135	
136	
137	
138	
142	
146	
149	








150	
151	
152	
153	
154	
156	
160	
161	
162	

164	
167	
168	
169	
170	
171	
172	
173	

183	
186	
187	
192	
196	
197	
199	
200	









201	
202	
203	
204	
205	
208	
209	
213	

215	
216	
220	
222	
223	
224	
225	
230	









231	
232	
233	
234	
235	
236	
237	









238	
241	
242	
243	
246	
247	
248	
251	
252	









253	
254	
256	
257	
258	
259	
261	
264	

265	
267	
268	
270	
271	
273	
275	
276	

277	
278	
279	
280	
281	
282	
286	
287	
288	









290	
291	
294	
295	
296	
301	
302	
307	










308	
313	
314	
315	
316	
317	
319	
320	

322	
323	
324	
325	
326	
327	
328	
329	









330	
331	
332	
336	
339	
340	
341	
342	

343	
344	
345	
347	
348	
349	
350	
351	
352	

354	
358	
360	
361	
362	
363	
364	
365	

366	
367	
368	
369	
370	
371	
372	
373	
374	

375	
376	
377	
378	
379	
381	
382	
383	
384	

385	
386	
387	
388	
389	
392	
393	
395	

396	
397	
398	
407	
409	
413	
415	

6. Una composición farmacéutica, que comprende el compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 5 y con un portador o excipiente farmacéuticamente aceptable.

7. Uso de un medicamento de acuerdo con cualquiera de las reivindicaciones 1 a 5 en la fabricación de un medicamento para el tratamiento o la prevención de la infección por VHB.